Table 3.

Baseline hrHPV type distribution and cumulative 18-month risks of ≥CIN2 and ≥CIN3 in women with an hrHPV-positive smear at baseline and a normal repeat smear at 6 months

hrHPV type at baselineAt risk
CIN2
CIN3
≥CIN2
≥CIN3
NRisk, % (95% CI)PRisk, % (95% CI)P
Irrespective of hrHPV status at 6 mo
    Any3731046 (4-10)2 (1-4)
    161047213 (7-24)0.0043 (1-11)0.548
    16 and/or 181359313 (8-22)0.00043 (1-10)0.206
    18 after exclusion 16312114 (5-37)0.0075 (1-28)0.037
    No 16, 18238111 (0-5)1 (0-5)
hrHPV-positive at 6 mo
    Any178949 (5-15)3 (1-7)
    16527222 (12-38)0.0025 (1-18)0.458
    16 and/or 18708320 (11-33)0.0015 (2-16)0.188
    18 after exclusion 16181113 (4-44)0.0487 (1-39)0.056
    No 16, 18108112 (1-9)1 (0-8)
hrHPV-negative at 6 mo
    Any139101 (0-10)0 (0-3)
    1637000 (0-32)0.9210 (0-9)1.000
    16 and/or 1847104 (1-24)0.1620 (0-8)1.000
    18 after exclusion 16101014 (2-67)0.1120 (0-31)1.000
    No 16, 1892000 (0-4)0 (0-4)